Raymond James initiated coverage on Vera Therapeutics Inc VERA, a late-stage drug developer in the autoimmune kidney space. The lead asset, atacicept, is a BLyS/APRIL dual inhibitor fusion protein currently in a Phase 3 study in IgA Nephropathy (IgAN).
In June, Vera Therapeutics announced that the Phase 2b ORIGIN trial of atacicept for IgA nephropathy (IgAN) met its primary and key secondary endpoints, with statistically significant and clinically meaningful reductions in proteinuria and stabilization of eGFR through week 36.
The analysts Ryan Deschner and Steven Seedhouse say that the encouraging Phase 2 IgA nephropathy study substantially de-risks the ongoing Phase 3 study, with accelerated approval expected in 2026.
The analyst initiates an Outperform rating and a price target of $29.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.